Literature DB >> 33490096

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis.

Rasmus Hvidbjerg Gantzel1, Mikkel Breinholt Kjær1, Tea Lund Laursen1, Konstantin Kazankov1,2, Jacob George3, Holger Jon Møller4, Henning Grønbæk1.   

Abstract

Macrophages are essential components of the human host immune system, which upon activation facilitates a broad pallet of immunomodulatory events including release of pro- or anti-inflammatory cytokines and chemokines, restoration of immune homeostasis and/or wound healing. Moreover, some macrophage phenotypes are crucially involved in fibrogenesis through stimulation of myofibroblasts, while others promote fibrolysis. During the last decades, the role of resident liver macrophages viz. Kupffer cells and recruited monocytes/macrophages in acute and chronic liver diseases has gained interest and been extensively investigated. Specifically, the scavenger receptors CD163 and mannose receptor (CD206), expressed by macrophages, are of utmost interest since activation by various stimuli induce their shedding to the circulation. Thus, quantifying concentrations of these soluble biomarkers may be of promising clinical relevance in estimating the severity of inflammation and fibrosis and to predict outcomes such as survival. Here, we review the existing literature on soluble CD163 and soluble mannose receptor in liver diseases with a particular focus on their relationship to hepatic fibrosis in metabolic associated fatty liver disease, as well as in chronic hepatitis B and C.
Copyright © 2021 Gantzel, Kjær, Laursen, Kazankov, George, Møller and Grønbæk.

Entities:  

Keywords:  fibrosis; hepatitis B virus; hepatitis C virus; liver; macrophages; mannose receptor; metabolic associated fatty liver disease; sCD163

Year:  2021        PMID: 33490096      PMCID: PMC7820116          DOI: 10.3389/fmed.2020.615599

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  89 in total

1.  Epidemiology of chronic liver diseases in the USA in the past three decades.

Authors:  Zobair M Younossi; Maria Stepanova; Youssef Younossi; Pegah Golabi; Alita Mishra; Nila Rafiq; Linda Henry
Journal:  Gut       Date:  2019-07-31       Impact factor: 23.059

2.  Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma.

Authors:  Holger Jon Møller; Niels Anker Peterslund; Jonas Heilskov Graversen; Søren Kragh Moestrup
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

Review 3.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

4.  Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.

Authors:  Sidsel Rødgaard-Hansen; Alexis St George; Konstantin Kazankov; Adrian Bauman; Jacob George; Henning Grønbæk; Holger Jon Møller
Journal:  Scand J Clin Lab Invest       Date:  2017-07-17       Impact factor: 1.713

Review 5.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.

Authors:  Leon A Adams; Quentin M Anstee; Herbert Tilg; Giovanni Targher
Journal:  Gut       Date:  2017-03-17       Impact factor: 23.059

6.  Expression of CD163 in the liver of patients with viral hepatitis.

Authors:  Atsushi Hiraoka; Norio Horiike; Sk Md Fazle Akbar; Kojiro Michitaka; Takami Matsuyama; Morikazu Onji
Journal:  Pathol Res Pract       Date:  2005       Impact factor: 3.250

7.  Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.

Authors:  Tea Lund Laursen; Cecilie Brøckner Siggard; Konstantin Kazankov; Thomas Damgaard Sandahl; Holger Jon Møller; Adrian Ong; Mark W Douglas; Jacob George; Britta Tarp; Lena Hagelskjaer Kristensen; Alex Lund Laursen; Akira Hiramatsu; Takashi Nakahara; Kazuaki Chayama; Henning Grønbaek
Journal:  Scand J Gastroenterol       Date:  2018-07-10       Impact factor: 2.423

Review 8.  CD163 and inflammation: biological, diagnostic, and therapeutic aspects.

Authors:  Anders Etzerodt; Søren K Moestrup
Journal:  Antioxid Redox Signal       Date:  2012-10-19       Impact factor: 8.401

9.  The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis.

Authors:  T D Sandahl; R McGrail; H J Møller; E Reverter; S Møller; F Turon; V Hernández-Gea; F Bendtsen; H Vilstrup; J C Garcia-Pagan; H Grønbaek
Journal:  Aliment Pharmacol Ther       Date:  2016-04-07       Impact factor: 8.171

10.  Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis.

Authors:  Mads Svart; Nikolaj Rittig; Niels Møller; Holger J Møller; Henning Gronbaek
Journal:  J Diabetes Investig       Date:  2018-06-30       Impact factor: 4.232

View more
  6 in total

1.  The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.

Authors:  Victoria Cairoli; Elena De Matteo; Paola Casciato; Beatriz Ameigeiras; María Victoria Preciado; Pamela Valva
Journal:  PLoS One       Date:  2022-07-07       Impact factor: 3.752

2.  Increased Serum Levels of sCD206 Are Associated with Adverse Prognosis in Patients with HBV-Related Decompensated Cirrhosis.

Authors:  Yue Zhang; Nanxi Xiao; Qi Liu; Yuan Nie; Xuan Zhu
Journal:  Dis Markers       Date:  2022-05-25       Impact factor: 3.464

3.  Macrophages and monocytes mediated activation of oxidative phosphorylation implicated the prognosis and clinical therapeutic strategy of Wilms tumour.

Authors:  Jialin Meng; Yonghao Chen; Xiaofan Lu; Qintao Ge; Feixiang Yang; Suwen Bai; Chaozhao Liang; Juan Du
Journal:  Comput Struct Biotechnol J       Date:  2022-06-27       Impact factor: 6.155

4.  Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study.

Authors:  Abdullah Ghassan Muhammad; Frederik Orm Hansen; Rasmus Hvidbjerg Gantzel; Karsten Fleischer Rex; Gerda Elisabeth Villadsen; Henning Grønbæk; Michael Lynge Pedersen
Journal:  Int J Circumpolar Health       Date:  2022-12       Impact factor: 1.941

5.  Risk Factor Analysis of Hepatic Encephalopathy and the Establishment of Diagnostic Model.

Authors:  Fangfang Chen; Jing Li; Wenjie Zhang; Caixia Mao; Yanxia Wang; Yan Qu; Shuju Tian; Fanhong Li
Journal:  Biomed Res Int       Date:  2022-07-19       Impact factor: 3.246

Review 6.  Inflammatory Effects of Bothrops Phospholipases A2: Mechanisms Involved in Biosynthesis of Lipid Mediators and Lipid Accumulation.

Authors:  Vanessa Moreira; Elbio Leiguez; Priscila Motta Janovits; Rodrigo Maia-Marques; Cristina Maria Fernandes; Catarina Teixeira
Journal:  Toxins (Basel)       Date:  2021-12-04       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.